Search Results 651-660 of 17001 for pharmacogenetics
ROCHESTER, Minn. — Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible for autosomal ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Researchers at Mayo Clinic are developing a Biobank of adult stem cell-rich breast organoids, a new research resource to facilitate normal and cancer stem ...
Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by ...
This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...
About this study. This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to ...
The researchers are trying to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss.
The Mayo Clinic Center for Individualized Medicine has achieved a milestone, finishing study recruitment after enrolling more than 100,000 participants in a ...
The purpose of this study is to: Prospectively characterize the dynamic systemic hemodynamic changes that occur during dynamic CT myelography. Prospectively ...
The Harris lab is investigating several types of kidney conditions. Autosomal dominant polycystic kidney disease (ADPKD). Our studies of ADPKD focus on genetic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.